Activins are growth and differentiation factors that have growth inhibitory effects on LNCaP and DU145, but not PC3, human prostate tumor cell lines. Activin-binding proteins, follistatins, block the inhibitory actions of exogenously added activins on LNCaP and DU145 tumor cell lines. Based on these in vitro observations using human prostate tumor cell lines, the aims of this study were to determine whether activins and follistatins are expressed in the human prostate in tissues from men with high grade prostate cancer. The expression and cellular localization of these proteins in malignant and nonmalignant regions of these tissues were compared to determine whether any changes occur with progression to malignancy. The results demonstrate that activins and follistatins are synthesized in tissues from men with high grade prostate cancer, and that messenger ribonucleic acid (mRNA) and protein for the activin ␤ A -and ␤ B -subunits and follistatin is expressed and localized to poorly differentiated tumor cells. In the nonmalignant regions, activin ␤ A and ␤ B subunit mRNA and proteins are predominantly localized to the epithelium. Follistatin mRNA was expressed in the basal epithelial cells and in the fibroblastic stroma; however, the localization of follistatin proteins using two specific antisera demonstrated a difference between the follistatin isoforms expressed in basal cells and the stroma. In the progression to malignancy, the colocalization of follistatin and activins to the tumor cells in vivo implies that resistance to the growth inhibitory effects of activin may be conferred by follistatins. (J Clin Endocrinol Metab 82: [3851][3852][3853][3854][3855][3856][3857][3858] 1997) 
men with high grade prostate cancer, and that messenger ribonucleic acid (mRNA) and protein for the activin ␤ A -and ␤ B -subunits and follistatin is expressed and localized to poorly differentiated tumor cells. In the nonmalignant regions, activin ␤ A and ␤ B subunit mRNA and proteins are predominantly localized to the epithelium. Follistatin mRNA was expressed in the basal epithelial cells and in the fibroblastic stroma; however, the localization of follistatin proteins using two specific antisera demonstrated a difference between the follistatin isoforms expressed in basal cells and the stroma. In the progression to malignancy, the colocalization of follistatin and activins to the tumor cells in vivo implies that resistance to the growth inhibitory effects of activin may be conferred by follistatins. (J Clin Endocrinol Metab 82: 3851-3858, 1997) A NUMBER of growth factors are involved in the progression to malignancy, including members of the transforming growth factor-␤ (TGF␤) superfamily. Based on the significant homology between the ␤-subunits, activins and inhibins are members of the TGF␤ superfamily and were first identified by their ability to regulate pituitary FSH. Inhibins inhibit FSH synthesis, whereas activins stimulate FSH synthesis (1) (2) (3) . Inhibins are glycoprotein hormones that are formed by the dimerization of two subunits, i.e. an ␣ with either ␤ A (inhibin A) or ␤ B (inhibin B). The inhibin ␤ A -and ␤ B -subunits can also form dimers called activins; three forms are known to exist: activin A (␤ A ␤ A ), activin B (␤ B ␤ B ), and activin AB (␤ A ␤ B ) (4) . Activins have been shown to have either proliferative or antiproliferative actions in reproductive, neuroendocrine, and erythroid tissues (5) (6) (7) . The effects of activins on cultured cells include induction of cell cycle arrest (8) and apoptosis (9) . Follistatins are structurally unrelated proteins (which also stimulate FSH secretion) (10) and bind activins, resulting in the neutralization of activin bioactivity (9, 11) . Follistatins are glycosylated monomeric proteins that arise from two alternatively spliced messenger ribonucleic acid (mRNA; FS315 and FS288), resulting in three protein cores; nine mol wt forms are postulated, and six have been identified and characterized (12) .
Recent studies from this laboratory have shown that inhibins, activins, and follistatins are synthesized by the human prostate gland. Thomas and colleagues (13) have reported mRNA expression for ␣-and ␤-subunits, the activin type II receptor, and both follistatin transcripts in tissues from men with benign prostatic hyperplasia. Proteins for activin A, activin ␤ A and ␤ B subunits, and follistatins were localized to the hyperplastic human prostate by immunohistochemical techniques (13) . More recently, inhibin ␣-subunit gene expression and protein synthesis were reported in benign prostate hyperplasia (BPH) tissues; however, in malignancy, down-regulation of inhibin ␣ gene expression occurred, and no mRNA or protein was observed in tissues from patient with high grade cancers (Mellor SL, Richards MG, Pedersen JS, Robertson DM, and Risbridger GP, submitted for publication). The loss of inhibin ␣ expression in vivo correlated with the failure to detect inhibin ␣ gene or protein in human prostate tumor cell lines (14 -16) . Together with the findings that functional deletion of the inhibin ␣-subunit results in the development of gonadal tumors in mice (17) , it was proposed that the inhibin ␣ gene is a tumor suppressor (16) .
In the absence of inhibin ␣ gene expression in high grade prostate cancer, it remains to be determined whether there is additional regulation of activin ␤-subunits, which may involve follistatin expression. In vitro studies using the human prostate tumor cell lines LNCaP, DU145, and PC3 have reported activin ␤-subunit and follistatin mRNAs and proteins (14, 15, 16, 18) , suggesting endogenous production of these proteins by prostate tumor cells. However, the effect of ex-ogenously added activins A and B was to inhibit the growth of LNCaP and DU145 cells; this response was not observed by PC3 cells, which appear resistant to the effects of activin A (18) . Although activin inhibits tumor cell proliferation in vitro, follistatin completely blocks this action on DU145 and LNCaP cells (18) . Therefore, the different in vitro observations may be due to the production of different levels of follistatins and/or protein forms by each of the tumor cell lines. The aim of this study was to determine whether poorly differentiated tumor cells from men with high grade prostate cancer express activin ␤ A -and ␤ B -subunits and follistatins. The patterns of localization and expression in malignant tissue were compared with those in nonmalignant regions of the same tissue specimens.
Materials and Methods

Patient samples
Needle biopsy specimens were obtained from a total of 25 patients undergoing transrectal ultrasound (TRUS)-guided biopsy. Carcinoma of the prostate was confirmed by histological examination (Melbourne Pathology, Collingwood, Australia), and the patients selected were those diagnosed with high grade prostate cancer and a Gleason score between 7-10. The specimens were obtained in accordance with the requirements and approval of the standing committee for human ethics and experimentation at Monash Medical Center and Monash University. Four-micron sections were cut from the specimens and used for immunohistochemistry and/or in situ hybridization (shown in Table 1 ) as described below. The expression or localization of inhibin ␤-subunits or follistatin was compared in nonmalignant regions and malignant (Gleason grade 4 or 5) regions of the tissue sections.
Immunohistochemical studies
Antibodies. Four antibodies for the inhibin ␤ A -and ␤ B -subunit proteins were used for these studies. The ␤ A and ␤ B Salk polyclonal antibodies (gifts from Dr. W. Vale) were raised in rabbits against synthetic human ␤ A or ␤ B peptides (19) . The ␤ A and ␤ B Groome monoclonal antibodies (gifts from Dr. N. P. Groome) were raised against synthetic human ␤ A or ␤ B peptides and have previously been used for the measurement of inhibin A and inhibin B (20, 21) .
Follistatin immunoreactivity was determined using two antisera. AS 202 was raised in an intact adult male New Zealand rabbit to purified bovine 39-kDa follistatin and has been used for the specific measurement of follistatin in serum samples by RIA (22) . On Western blot analysis, the cross-reaction of bovine follistatin with AS 202 was approximately 16 times greater than that with human recombinant FS288 per ng protein (de Kretser, D. M., unpublished observation). Preabsorption of AS 202 was achieved by incubating 1 g bovine follistatin with 25 L of a 1:500 dilution of AS 202 overnight at 4 C. The mixture was centrifuged at 12,000 ϫ g, and the supernatant was collected and used accordingly. The OxB288 antibody was raised to human recombinant FS288 and was generously provided by Dr. L. Evans (23) .
Immunohistochemistry. Sections were dewaxed, rehydrated, and placed in Target Retrieval Solution (Dako, Carpenteria, CA). Antigenic sites were exposed by microwaving the sections (2.25 watts/mL⅐min for 3 min, followed by 0. 
In situ hybridization studies
Probe synthesis. Digoxygenin (DIG)-labeled riboprobes were prepared using the Boehringer Mannheim riboprobe labeling kit. Sense and antisense complementary RNA (cRNA) probes were generated from rat inhibin ␤ A and ␤ B (24) and rat follistatin (25) partial clones (370, 390, and 267 bp, respectively).
Hybridization. Sections were dewaxed, rehydrated, treated with 0.2 mol/L HCl, and then washed in diethyl pyrocarbonate-treated water (twice, 5 min each time). Sections were digested with proteinase K (Boehringer Mannheim) for 30 min at 37 C. After incubation in 0.2% glycine for 10 min at 4 C, sections were equilibrated in 0.1 mol/L triethanolamine and acetylated in 0.25% acetic anhydride for 5 min. After rinsing in diethyl pyrocarbonate-treated water, sections were prehybridized for a minimum of 30 min. Prehybridization solution contains 3 ϫ SSC (1 ϫ SSC is 0.15 mol/L sodium chloride and 15 mmol/L sodium citrate, pH 7), 1 ϫ Denhardt's solution, 50% deionized formamide, 66 mmol/L phosphate buffer (pH 8), 1000 g/mL herring sperm DNA, and 200 g/mL transfer RNA.
Sections were hybridized overnight at 42 C in hybridization buffer (prehybridization solution plus 10% dextran sulfate) containing a predetermined concentration (200 -1000 ng/mL) of riboprobe. Excess probe was removed by sequential 15-min washes in 2 ϫ SSC at room temperature, 2 ϫ SSC at 42 C, 1 ϫ SSC at 42 C, and finally either 0.1 or 0.5 ϫ SSC (depending on the probe employed) at 42 C. 
Immunohistochemistry
In situ hybridization
ϩ, Samples that were analyzed for the expression and/or localization of proteins.
Anti-DIG detection. The tissues were briefly washed in buffer 1 (0.1 mol/L maleic acid and 0.15 mol/L sodium chloride, pH 7.5) before anti-DIG antibody detection. Anti-DIG Fab fragments conjugated to alkaline phosphatase (Boehringer Mannheim) were diluted to 1:1000 in 1% blocking reagent in buffer 1, and the sections were incubated for 1 h at room temperature. Alkaline phosphatase activity was detected using NBT/BCIP substrate (NBT/BCIP 1-step, Pierce Chemical Co., Rockford, IL), the reaction was stopped by immersion in water, and the sections were permanently mounted with GVA Histomount (Zymed).
Results
␤ A expression and localization
The pattern of immunostaining in the nonmalignant and malignant regions of tumor tissue obtained from patients with high grade prostate cancer using two specific ␤ A -subunit antibodies is shown in Fig. 1 . Using the ␤ A Groome antibody, positive immunoreactivity was observed in basal and secretory epithelial cells in the nonmalignant regions of tissue (Fig. 1, A and B) . Immunoreactivity for ␤ A -subunit was also observed in tumor cells from adjacent regions of the tissue containing poorly differentiated tumor (Fig. 1, D and E). No immunostaining was observed in either the nonmalignant or malignant regions of control sections (Fig. 1, C and  F) . Using the ␤ A Salk antibody, a similar pattern of immunostaining was observed; the nonmalignant epithelium showed positive immunoreactivity that was localized to the basal and secretory cells (Fig. 1, G and H, indicated by the  arrow) , although the intensity of staining was highly variable. In addition, weaker stromal staining was observed in these nonmalignant regions of the tissue sections, as demonstrated by the arrows (Fig. 1, G and H) . The malignant epithelial tumor cells showed consistent and positive staining of localization for ␤ A -subunit protein (Fig. 1, J and K) . No positive immunoreactivity was observed with rabbit IgG (Fig. 1,  I and L).
In situ hybridization confirmed that mRNA for ␤ A -subunit was present in the nonmalignant regions of the sections from men with high grade prostate cancer and was predominantly localized to secretory and/or basal cells in the epithelium (Fig. 1M) . Isolated groups of cells in the stroma also expressed ␤ A mRNA (shown by the arrows in Fig. 1M ). The expression of ␤ A -subunit mRNA was detected in the malignant cells of the adjacent regions of tumor tissue (Fig. 1N) . Using the sense ␤ A probe, no mRNA expression was detected (Fig. 1, O and P) .
␤ B -subunit expression and localization
The pattern of expression and localization for ␤ B -subunit in nonmalignant and malignant regions of tissue obtained from patients with high grade prostate cancer is shown in Fig. 2 . Using the ␤ B Groome antibody, positive immunoreactivity was primarily localized to the epithelial compartment of nonmalignant regions of tissue, with more intense staining of ␤ B -subunit observed in the basal cells (Fig. 2, A  and B) . In adjacent malignant regions, immunoreactivity for ␤ B -subunit was localized to the tumor cells (Fig. 2, D and E) , no positive immunostaining was observed in the control sections (Fig. 2, C and F) . Using the ␤ B Salk antibody, immunoreactivity was localized to the nonmalignant epithelial tissue and was predominantly located in the basal, rather than the secretory, epithelial cells (Fig. 2, G and H) . Positive immunoreactivity for ␤ B -subunit was also present in the malignant tumor cells (Fig. 2, J and K) . Positive immunoreactivity was not observed with rabbit IgG (Fig. 2, I and L) .
mRNA for the ␤ B -subunit was expressed in the malignant and nonmalignant epithelium. In the latter regions, the level of expression of ␤ B -subunit mRNA was greater in the basal cells than in the secretory epithelial cells and was consistent with the immunoreactivity in the basal cells using both of the ␤ B antibodies (Fig. 2M) . mRNA for ␤ B -subunit was also expressed in the tumor cells (Fig. 2N) . No mRNA expression was detected using the ␤ B sense probe in either malignant or nonmalignant regions of the biopsy (Fig. 2, O and P) .
Localization and expression of follistatin
Using the polyclonal antibody AS 202, follistatin immunoreactivity was localized to patchy regions of stromal tissue in the nonmalignant regions of needle biopsies from men with high grade prostate cancer (Fig. 3, A and B) . No immunoreactivity was observed in the epithelium or in the control sections incubated with AS 202 preabsorbed with bovine follistatins (Fig. 3C ). In contrast, using the OxB288 antibody, positive immunoreactivity was localized to the basal cells of the epithelium and was not recorded in surrounding stromal tissues (Fig. 3, G and H) . In the regions of poorly differentiated tumor, intense positive immunoreactivity was localized to the malignant epithelial cells using both follistatin antibodies (Fig. 3, D and E, and J and K). No positive localization was observed with rabbit IgG (Fig. 3, F and L).
In the nonmalignant tissues, follistatin mRNA was expressed in patches of cells within the stromal tissue (Fig. 3M) , consistent with the immunoreactivity observed with AS 202 (Fig. 3, A and B) . Follistatin mRNA was also expressed in the nonmalignant epithelium, specifically in the basal cells (Fig.  3M) ; this site of expression of follistatin mRNA correlated with the detection of immunoreactivity for follistatin protein using the OxB288 antibody (Fig. 3, G and H) . In the malignant tumor regions, follistatin mRNA was expressed in the tumor cells (Fig. 3N) , which is consistent with the positive immunoreactivity that was recorded using both follistatin antibodies (Fig. 3, D and E, and J and K). mRNA expression was not detected using the follistatin sense riboprobe (Fig. 3, O and P).
Discussion
This study describes the pattern of expression and localization of activin ␤-subunits and activin-binding proteins, follistatins; the results demonstrate that there is a difference between the malignant and nonmalignant regions of tissue from men with high grade prostate cancer.
In the nonmalignant regions of the tissue sections from men with high grade prostate cancer, activin subunits ␤ A and ␤ B were detected in the epithelium, consistent with our previous observations using tissues from men with BPH (13) . Expression of mRNAs for the activin subunits in the epithelium was observed and, therefore, confirmed that the prostatic epithelium is a site of synthesis and expression of activin ligands. Although the expression of activin ␤ A -subunit mRNA was detected in all basal and secretory cells of the nonmalignant epithelia, the protein was not detected in a uniform pattern using the Salk ␤ A antibody. This pattern of variable staining, where some glands showed intense staining and others showed none at all, was previously observed using an antibody to dimeric activin A to detect this ligand in tissue sections from men with BPH (13) . However, the Groome monoclonal antibody consistently detected ␤ A -subunit protein in basal and secretory cells of the nonmalignant epithelia, which was identical to the uniform detection of mRNA. The reason why there are differences using the two different ␤ A antibodies is not known.
In contrast to those of ␤ A , the expression and synthesis of ␤ B were consistently observed to be predominantly localized to the basal, rather than the secretory, cells. This pattern of subunit localization was identical using both antibodies and was consistent with the expression of ␤ B mRNA. The predominant synthesis and production of the ␤ A -and ␤ B -subunits in the prostatic epithelial cells provides these cell types with the capacity to form homo-or heterodimers of the ␤-subunits and, thus, activin A, B, or AB ligands. This laboratory has previously demonstrated that the nonmalignant epithelium expresses and produces the inhibin ␣-subunit (13), and therefore, the capacity to synthesize inhibin A or B must also reside within these cells.
The actions of inhibin and activin ligands on nonmalignant prostatic epithelium have yet to be documented. In normal and hyperplastic acini of human prostate, it has been reported that 70% of proliferating cells are localized within the basal cell layer, which has led to the speculation that basal cells have an important role in the proliferative activity of the epithelium (26) . It is noteworthy that the basal cells are the predominant site of synthesis of the activin and inhibin subunits, suggesting that these ligands have the potential to influence renewal of the prostatic epithelium. In the human prostate tumor cell lines LNCaP and DU145, a growth inhibitory response to activin A and B has been reported (18, 27, 28) , and it is possible that these ligands have a similar action on the nonmalignant epithelium. Indeed, this might be predicted, as activins are known to have antiproliferative actions in other cells and tissues (5-7) and to induce apoptosis in certain cell lines (9) .
In many instances, the inhibins have effects that oppose those of activins in some cells and tissues (5, 29) . The demonstration that inhibin ␣-subunits are synthesized by the nonmalignant prostate suggests that they may regulate the actions of activins on the nonmalignant epithelium. In contrast, the ␣-subunit is down-regulated in tissues from men with high grade prostate cancer (Mellor SL, Richards MG, Pedersen JS, Robertson DM, and Risbridger GP, submitted for publication), and human prostate tumor cells do not express inhibin ␣-subunit in vitro (14 -16) . The loss of ␣-subunit with the continued expression of the ␤-subunits results in the synthesis of activins, but not inhibins, in the malignant epithelium. However, the growth inhibitory actions of activin A and B on some prostatic tumor cell lines are not consistent with the malignant characteristics of these cells (18) , and a mechanism for conferring resistance to activin ligands must be considered. By analogy with TGF␤, it is possible that there are inactivating mutations of the activin receptors (30) , but an alternate means of regulating activin action is via follistatins, i.e. binding proteins with a specific and high affinity for activins.
Follistatin neutralizes the diverse actions of activins, including apoptosis (9) , in various cells and tissues by forming an inactive complex with activin. The results described herein demonstrate the expression and localization of follistatin in tumor cells from men with high grade prostate cancer. The localization of the activin subunits and follistatin to the malignant epithelial cells implies that follistatin neutralizes the bioactivity of the activin ligands in poorly differentiated prostate tumors. This is consistent with the in vitro observation that follistatin neutralizes the growth inhibitory effects of exogenously added activin A to the human prostate tumor cell lines LNCaP and DU145 (18) ; in contrast, PC3 cells are resistant to exogenously added activin A (18) . The only difference between the three prostate tumor cell lines that we have observed is the expression of FS288 mRNA by the activin-resistant PC3 cells, but not by LNCaP or DU145 cells in which the predominant mRNA is FS315 (18) . The relative levels and types of follistatin produced by the three prostate tumor cell lines are not known. It has been shown that FS288 has a higher neutralizing activity than FS315 (12) , and therefore, it is possible that the presence of FS288 is important in conferring activin resistance, as demonstrated in the PC3 cells. In poorly differentiated tumor tissue, follistatin mRNA and proteins, detected by two different antibodies, localize with activin subunit immunoreactivity, which implies that the tumor cells may be resistant to activin in vivo due to the presence of follistatin.
In the nonmalignant tissues adjacent to the high grade tumors, mRNA expression for follistatin was detected in epithelial basal cells and stroma; using OxB288, FS288 protein was localized predominantly to the basal cells. This suggests that the interplay between activin and follistatin is important in regulating activin's action on basal cells, but the effect of activins on basal cells is not known. In the nonmalignant stromal tissue, follistatin mRNA is expressed, and protein was localized using AS 202, but not the OxB288 antibody. These results suggest that the follistatin proteins produced in basal and stromal cells are different. Furthermore, in malignant and nonmalignant tissues, these data suggest that the expression of follistatin mRNA results in the production of different follistatin isoforms in specific cell types. The relative levels of follistatin proteins and whether they are bound or unbound to activin may also change in the progression to malignancy. The ability to resolve these issues requires the further development of methods that can discriminate among the different forms of follistatin in bound and unbound forms in situ.
